Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Marcelo V Negrao, MD
CONTACT
Lead
M.D. Anderson Cancer Center
Primary Objective: To evaluate the safety and tolerability of iza-bren in combination with adagrasib for treatment of KRAS G12C-mutant NSCLC patients that progressed on KRAS G12C inhibitors. Secondary Objectives: * To evaluate the preliminary efficacy of iza-bren in combination with adagrasib for treatment of KRAS G12C-mutant NSCLC patients that progressed on KRAS G12C inhibitors. * To evaluate the pharmacokinetics of iza-bren upon combination treatment with adagrasib. * To evaluate immunogenicity against iza-bren upon combination treatment with adagrasib. * To evaluate the incidence of anti-drug antibody (ADA) formation to Iza-bren when it is administered in combination with adagrasib, and to assess the potential effect of ADA on PK, PD and safety. * To evaluate EGFR and HER3 tumor expression as determinants of clinical outcomes to study regimen. * To evaluate circulating tumor DNA (ctDNA) as a determinant of clinical outcome to study regimen. * To evaluate mechanisms of resistance to study regimen.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted